Inter partes review

Wolf Greenfield Promotes Most Attorneys to Shareholder in Firm’s History in 2021

Retrieved on: 
Monday, January 4, 2021
Technology, Networks, Legal, Professional services, Intellectual property law, United States patent law, Patent law, Inter partes review, Patentability

Wolf Greenfield is pleased to announce the promotion of seven attorneys to the position of shareholder, effective January 1, 2021, marking the most shareholder elevations made at one time in the firms history.

Key Points: 
  • Wolf Greenfield is pleased to announce the promotion of seven attorneys to the position of shareholder, effective January 1, 2021, marking the most shareholder elevations made at one time in the firms history.
  • We are thrilled to have the ability to promote a record number of well-deserving individuals to shareholder in this most unusual year, said Tim Oyer, Wolf Greenfields President and Managing Partner.
  • David Cauble counsels clients on filing strategy, portfolio development and IP risk management in relation to chemical and pharmaceutical technologies.
  • His experience includes patent preparation and prosecution, appeals and inter partes review, as well as patentability, freedom-to-operate and opinion work.

Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents

Retrieved on: 
Wednesday, October 14, 2020
United States patent law, Inter partes review, PTAB, United Therapeutics, Inter partes

9,604,901 (901) and concurrently denied institution on 9,593,066 (066), both owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso (treprostinil).

Key Points: 
  • 9,604,901 (901) and concurrently denied institution on 9,593,066 (066), both owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso (treprostinil).
  • For 901, the PTAB Institution Decision states that based on the information presented, we institute an inter partes review of claims 19 of the 901 patent.
  • Mr. Fowler added, The Liquidia management team and our board are committed to providing PAH patients with alternative treatment options, like LIQ861, that we believe they need and deserve.
  • In July, UTC filed an amended complaint asserting infringement of an additional recently issued U.S. Patent No.

Worlds Inc. vs. Microsoft in Patent Infringement Lawsuit Related to “Minecraft”

Retrieved on: 
Tuesday, September 29, 2020
Inter partes review, PTAB, United States patent law

In the complaint, Worlds accuses Microsoft and its Minecraft video game product of infringing Worlds' U.S. Patent No.

Key Points: 
  • In the complaint, Worlds accuses Microsoft and its Minecraft video game product of infringing Worlds' U.S. Patent No.
  • Finally, on January 14, 2020, the 501 Patent emerged from the inter partes review process with all claims intact.
  • Our expert legal team at DBJG defended the 501 Patent before the PTAB, and convinced the CAFC to reverse and remand unfavorable PTAB decisions against Worlds patents," stated Thom Kidrin, Worlds Inc. CEO.
  • Worlds, Inc. (OTCQB: WDDD), is a leading intellectual property developer and licensee of patents related to 3D online virtual worlds.

 Axonics® Provides Update on Inter Partes Review Proceedings

Retrieved on: 
Thursday, September 24, 2020
Professional services, Medical devices, Health, Legal, General Health, Biotechnology, Inter partes review, United States patent law, Medtronic, IPR, Patent

On March 16, Axonics filed seven inter partes review (IPR) petitions contesting the validity of certain Medtronic patents.

Key Points: 
  • On March 16, Axonics filed seven inter partes review (IPR) petitions contesting the validity of certain Medtronic patents.
  • Cohen continued, Since its founding, Axonics has focused on innovation and developing best-in-class SNM solutions for patients.
  • Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.
  • Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

NajingTech's lawsuit against Nanosys halted after U.S. Patent Office questions validity of U.S. Patent No. 7,105,051

Retrieved on: 
Tuesday, September 1, 2020
Intellectual property law, United States patent law, Inter partes review, Nanosys, United States Patent and Trademark Office, Patent, Inter partes

Silicon Valley-based Nanosys has worked hard over the past two decades to create a vibrant, growing marketplace for its proprietary quantum dot technology.

Key Points: 
  • Silicon Valley-based Nanosys has worked hard over the past two decades to create a vibrant, growing marketplace for its proprietary quantum dot technology.
  • On August 25, 2020, the trial court brought this lawsuit to a halt because the U.S. Patent Office had decided to review the validity of the '051 patent.
  • In particular, on August 18, 2020, the Patent Office instituted an Inter Partes Review of the '051 patent, which is special proceeding for the Office to assess the validity of issued patents.
  • In instituting this proceeding, the Patent Office found that Nanosys "has established a reasonable likelihood of prevailing in showing that claims 111 and 1323 of the '051 patent are unpatentable."

Guardian Alliance Technologies DENIED Again by USPTO Judges in Attempt to Invalidate Miller Mendel's eSOPH Patent

Retrieved on: 
Monday, August 3, 2020
Intellectual property law, United States patent law, PTAB, Patent Trial and Appeal Board, Inter partes review, Patent and Trademark Office

WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- The United States Patent and Trademark Office (USPTO), Patent Trial and Appeal Board (PTAB) has again, for the second time, DENIED Guardian Alliance Technologies' attempt to invalidate Miller Mendel's 188 Patent.

Key Points: 
  • WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- The United States Patent and Trademark Office (USPTO), Patent Trial and Appeal Board (PTAB) has again, for the second time, DENIED Guardian Alliance Technologies' attempt to invalidate Miller Mendel's 188 Patent.
  • Miller Mendel, Inc. asserted in a federal lawsuit filedOctober 9, 2018, that Guardian Alliance Technologies' platform infringes on certain claims in Miller Mendel's 188 patent.
  • The patent was granted to Tyler Miller, Miller Mendel's Founder, President and CEO onJune 30, 2015, and licensed exclusively to Miller Mendel, Inc.
  • OnMarch 26, 2020, the USPTO PTAB judges issued a 22-page decision , denying Guardian Alliance Technologies' Inter Partes Review request.

Shockwave Announces Decisions From the U.S. Patent and Trademark Office on Inter Partes Review Proceeding

Retrieved on: 
Wednesday, July 8, 2020
Intellectual property law, United States patent law, Patent law, Patent Trial and Appeal Board, PTAB, United States Patent and Trademark Office, Patent, Versata Development Group, Inc. v. SAP America, Inc., Inter partes review

In December 2018, CSI filed petitions for IPR with the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to challenge the validity of three of Shockwaves issued patents.

Key Points: 
  • In December 2018, CSI filed petitions for IPR with the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to challenge the validity of three of Shockwaves issued patents.
  • The PTAB ruled today that a key claim in U.S. Patent No 8,956,371 (the 371 patent) is valid.
  • This claim is generally directed to a device that creates shockwaves inside of a balloon catheter that is delivered over a guidewire.
  • Further, the PTAB ruled today that some claims of the U.S. Patent No 8,956,371 are invalid and that all claims of U.S. Patent No 8,728,091 (the 091 patent) are invalid.

Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents

Retrieved on: 
Wednesday, June 3, 2020
Intellectual property law, United States patent law, Inter partes review, PTAB, United States Patent and Trademark Office

Regeneron had filed oppositions against the Japanese Bradley patents, but the Japanese Bradley patents were upheld in unappealable decisions by the Japanese Patent Office.

Key Points: 
  • Regeneron had filed oppositions against the Japanese Bradley patents, but the Japanese Bradley patents were upheld in unappealable decisions by the Japanese Patent Office.
  • In September 2019, Regeneron filed requests1 at the US Patent Offices PTAB (Patent Trial & Appeal Board2) seeking Inter Partes Review (IPR) proceedings against 4 of the Bradley US patents.
  • In January 2020, Regeneron filed a further request for the PTAB to instigate IPR proceedings on a 5th Kymab patent4.
  • Regeneron appealed to the Australian Federal Court, but in May 2020 Regeneron agreed to discontinue its appeal and Kymabs Australian patent is now upheld.

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings

Retrieved on: 
Friday, May 29, 2020
Eli Lilly and Company, Hormones, Branches of biology, Peptide hormones, Recombinant proteins, RTT, Life sciences, Sanofi, Insulin glargine, Mylan, Inter partes review, Insulin

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. Patent Nos.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. Patent Nos.
  • Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No.
  • The '844 and '652 patents are the only remaining patents asserted by Sanofi against Mylan's insulin glargine products.
  • Sanofi's total IQVIA sales for the 12 months ending March 31, 2020, were approximately $1.71 billion for Lantus 100 Units/mL and about $4.32 billion for Lantus SoloSTAR.

Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron

Retrieved on: 
Tuesday, April 14, 2020
Intellectual property law, United States patent law, Patent Trial and Appeal Board, PTAB, United States Patent and Trademark Office, Patent, Inter partes review, Versata Development Group, Inc. v. SAP America, Inc.

The patents are US patent numbers 9,434,782; 9,505,827; 9,447,177; and 10,165,763 known as the Bradley Patents.

Key Points: 
  • The patents are US patent numbers 9,434,782; 9,505,827; 9,447,177; and 10,165,763 known as the Bradley Patents.
  • Regeneron had filed oppositions against the Japanese Bradley patents, but these were upheld in unappealable decisions by the Japanese Patent Office.
  • Regeneron had requested that the U.S. Patent and Trademark OfficesPatent Trial and Appeal Board (PTAB) commence interpartes reviews (IPRs) of the four patents in question, contending that certain prior art references invalidated the patents.
  • However, Regeneron did not persuade the PTAB who instead declined to continue the IPR proceedings.